Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • CG-806 for B-cell Tumors
    • CG-806 for Myeloid Tumors
    • APTO-253
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • CG-806 for CLL & NHL
    • CG-806 for AML
    • APTO-253 for AML & MDS
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Presentations

News

News

  • Press Releases
  • Presentations
  • Events
Aptose Biosciences Inc Corporate Presentation February 2021

Aptose Biosciences Inc Corporate Presentation February 2021

Feb 16, 2021
Aptose Corporate Update at ASH 2020

Aptose Corporate Update at ASH 2020

Dec 6, 2020
2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

Dec 6, 2020
2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

Dec 5, 2020
2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas

2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas

Jun 22, 2020
2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL

2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL

Jun 12, 2020
2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL

2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL

Apr 27, 2020
Key Opinion Leader Symposium: CG-806 for AML

Key Opinion Leader Symposium: CG-806 for AML

Feb 5, 2020
2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Dec 9, 2019
2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Dec 8, 2019
RSS
  • 1
  • 2
  • 3
  • Next »
© 2021 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap